Clinical Trial

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2018-08-21; most recent amendment 2026-01-06.
Status change: Recruiting → Active, Not Recruiting 2024-03-15
Status change: Not Yet Recruiting → Recruiting 2019-01-02
Trial Details
NCT Number NCT03642626
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Enrollment 150 participants
Start Date 2018-12-18
Primary Completion 2024-02-09 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-23